Figures & data
Table 1 Subjects’ baseline characteristics according to prescription of long-acting antipsychotics
Figure 1 Patients’ disposition throughout the study.
Abbreviations: AP, antipsychotics; flu, fluphenazine; ris, risperidone; zucl, zuclopenthixol.
Figure 2 Kaplan–Meier description of the proportion of the sample surviving without relapse during follow-up (n = 597).
Figure 3 Distribution of the doses of LAI risperidone at each study assessment among patients treated with this medication.
Figure 4 Kaplan–Meier description of the proportion of patients receiving concomitant oral antipsychotics together with LAI antipsychotics, regardless of whether the LAI antipsychotic was started at baseline or during the study.
Table 2 Resource utilization and direct health care costs according to prescription of long-acting antipsychotics at baseline
Figure 5 Pie chart showing the breakdown of direct health care costs throughout the study year incurred by patients who started a long-acting injectable antipsychotic at recruitment (n = 92).
